Hyperpolarized magnetic resonance: A novel technique for the in vivo assessment of cardiovascular disease

Circulation

Volumn 124, Issue 14, 2011, Pages 1580-1594

  Schroeder, Marie A ^a   Clarke, Kieran ^a   Neubauer, Stefan ^a   Tyler, Damian J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCARNITINE; ACETYLCARNITINE C 13; AMMONIA N 13; BICARBONATE; BICARBONATE C 13; CARBON 11; CARBON 13; CARNITINE; CARNITINE PALMITOYLTRANSFERASE INHIBITOR; CITRIC ACID; CITRIC ACID C 13; DECANOIC ACID DERIVATIVE; FLUORO 6 THIAHEPTADECANOIC ACID F 18; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; GLUCOSE C 11; GLUTAMIC ACID; GLUTAMIC ACID C 13; LACTIC ACID; LACTIC ACID C 13; OXYGEN 17; PALMITIC ACID C 11; PHOSPHORUS 31; PYRUVIC ACID; PYRUVIC ACID C 13; SODIUM 23; TRIMETAZIDINE; UNCLASSIFIED DRUG; UREA C 13;

ANGIOCARDIOGRAPHY; ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MAGNETIC RESONANCE; CARNITINE DEFICIENCY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETIC CARDIOMYOPATHY; DIAGNOSTIC ACCURACY; DRUG CONTRAINDICATION; DRUG METABOLISM; DYNAMIC NUCLEAR POLARIZATION; ENZYME ACTIVATION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART MUSCLE PERFUSION; HUMAN; HYPERPOLARIZATION; HYPERTHYROIDISM; ISCHEMIC HEART DISEASE; LOW TEMPERATURE; MAGNETIC FIELD; MICROWAVE IRRADIATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REPERFUSION INJURY; STRESS;

ANIMALS; BICARBONATES; CARBON ISOTOPES; CARDIOMYOPATHIES; CARDIOVASCULAR DISEASES; DIAGNOSTIC TECHNIQUES, CARDIOVASCULAR; ENERGY METABOLISM; FORECASTING; GLYCOLYSIS; HEART FAILURE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MYOCARDIAL ISCHEMIA; MYOCARDIUM; NEOPLASMS, EXPERIMENTAL; PYRUVATE DEHYDROGENASE COMPLEX; SENSITIVITY AND SPECIFICITY; UREA;

EID: 80053469087     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.024919     Document Type: Article

References (124)

1. Karamitsos TD, Francis JM, Myerson S, Selvanayagam JB, Neubauer S. The role of cardiovascular magnetic resonance imaging in heart failure. J Am Coll Cardiol. 2009;54:1407-1424.
2. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation; 2010;121:e46-e215.
3. British Heart Foundation statistics website. http://www.bhf.org.uk/heart- health/statistics.aspx. Accessed August 31, 2011.
4. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z, Ruilope L, Sans-Menendez S, Op Reimer WS, Weissberg P, Wood D, Yarnell J, Zamorano JL, Walma E, Fitzgerald T, Cooney MT, Dudina A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Funck-Brentano C, Filippatos G, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Altiner A, Bonora E, Durrington PN, Fagard R, Giampaoli S, Hemingway H, Hakansson J, Kjeldsen SE, Larsen L, Mancia G, Manolis AJ, Orth-Gomer K, Pedersen T, Rayner M, Ryden L, Sammut M, Schneiderman N, Stalenhoef AF, Tokgozoglu L, Wiklund O, Zampelas A. European guidelines on cardiovascular disease prevention in clinical practice: full text: Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007;14(suppl 2):S1-S113. (Pubitemid 47339826)
5. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:1977-2016.
6. Neubauer S. The failing heart: an engine out of fuel. N Engl J Med. 2007;356:1140-1151. (Pubitemid 46425598)
7. Chen L, Bai S, Su W, Song X, Zhang P, Li L, Ji JJ. Transient oxygenglucose deprivation causes immediate changes in redox activity in mouse brain tissue. Brain Res. 2011;1390:99-107.
8. Bailey IA, Gadian DG, Matthews PM, Radda GK, Seeley PJ. Studies of metabolism in the isolated, perfused rat heart using 13C NMR. FEBS Lett. 1981;123:315-318. (Pubitemid 11148767)
9. Kim RJ, Lima JA, Chen EL, Reeder SB, Klocke FJ, Zerhouni EA, Judd RM. Fast 23Na magnetic resonance imaging of acute reperfused myocardial infarction. Potential to assess myocardial viability. Circulation. 1997;95:1877-1885. (Pubitemid 27164406)
10. Szczepaniak LS, Babcock EE, Schick F, Dobbins RL, Garg A, Burns DK, McGarry JD, Stein DT. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Physiol. 1999;276: E977-E989. (Pubitemid 29249618)
11. Ruiz-Cabello J, Barnett BP, Bottomley PA, Bulte JW. Fluorine (19F) MRS and MRI in biomedicine. NMR Biomed. 2011;24:114-129.
12. Buscher K, Judenhofer MS, Kuhlmann MT, Hermann S, Wehrl HF, Schafers KP, Schafers M, Pichler BJ, Stegger L. Isochronous assessment of cardiac metabolism and function in mice using hybrid PET/MRI. J Nucl Med. 2010;51:1277-1284.
13. Boss A, Bisdas S, Kolb A, Hofmann M, Ernemann U, Claussen CD, Pfannenberg C, Pichler BJ, Reimold M, Stegger L. Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT. J Nucl Med. 2010;51:1198-1205.
14. Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH, Servin R, Thaning M, Golman K. Increase in signalto-noise ratio of 10,000 times in liquid-state NMR. Proc Natl Acad Sci USA. 2003;100:10158-10163. (Pubitemid 37071849)
15. Golman K, Zandt R, Thaning M. Real-time metabolic imaging. Proc Natl Acad Sci USA. 2006;103:11270-11275. (Pubitemid 44156508)
16. "Watchful waiting" has a new set of eyes. UCSF prostate cancer news release. http://www.ucsf.edu/news/2010/11/5846/new-prostate-cancerimaging- shows-real-time-tumor-metabolism.
17. Gallagher F, Kettunen M, Brindle K. Biomedical applications of hyperpolarized 13C magnetic resonance imaging. June 1, 2009. DOI: 10.1016/j.pnmrs.2009.06.001.
18. J Prog Nucl Magn Reson Spectrosc. 2009;55:285-295.
19. Chen J, Einstein AJ, Fazel R, Krumholz HM, Wang YF, Ross JS, Ting HH, Shah ND, Nasir K, Nallamothu BK. Cumulative exposure to ionizing radiation from diagnostic and therapeutic cardiac imaging procedures. J Am Coll Cardiol. 2010;56:702-711.
20. Budoff MJ, Gupta M. Radiation exposure from cardiac imaging procedures. J Am Coll Cardiol. 2010;56:712-714.
21. Leach AM, Urbahn J, Andersen D, Clarke N, Skloss T, Ardenkjaer-Larsen JH. A DNP polarizer designed for clinical use. Proc Int Soc Magn Reson Med. 2010;18:3260.
22. Budinger TF. Perspectives on imaging modalities. Cardiovasc Intervent Radiol. 1989;12:223-225. (Pubitemid 19281241)
23. Randle PJ. Fuel selection in animals. Biochem Soc Trans. 1986;14: 799-806.
24. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev. 2005;85:1093-1129. (Pubitemid 40894649)
25. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1:785-789.
26. Reed LJ. Regulation of mammalian pyruvate dehydrogenase complex by a phosphorylation-dephosphorylation cycle. Curr Top Cell Regul. 1981; 18:95-106.
27. Linn TC, Pettit FH, Reed LJ. Alpha-keto acid dehydrogenase complexes, X: regulation of the activity of the pyruvate dehydrogenase complex from beef kidney mitochondria by phosphorylation and dephosphorylation. Proc Natl Acad Sci USA. 1969;62:234-241.
28. Hansford RG, Cohen L. Relative importance of pyruvate dehydrogenase interconversion and feed-back inhibition in the effect of fatty acids on pyruvate oxidation by rat heart mitochondria. Arch Biochem Biophys. 1978;191:65-81. (Pubitemid 9050309)
29. Taegtmeyer H, Golfman L, Sharma S, Razeghi P, van Arsdall M. Linking gene expression to function: metabolic flexibility in the normal and diseased heart. Ann N Y Acad Sci. 2004;1015:202-213. (Pubitemid 38879491)
30. Collins-Nakai RL, Noseworthy D, Lopaschuk GD. Epinephrine increases ATP production in hearts by preferentially increasing glucose metabolism. Am J Physiol. 1994;267:H1862-H1871.
31. Owen OE, Mozzoli MA, Boden G, Patel MS, Reichard GA Jr, Trapp V, Shuman CR, Felig P. Substrate, hormone, and temperature responses in males and females to a common breakfast. Metabolism. 1980;29: 511-523. (Pubitemid 10123239)
32. Merritt ME, Harrison C, Storey C, Jeffrey FM, Sherry AD, Malloy CR. Hyperpolarized 13C allows a direct measure of flux through a single enzyme-catalyzed step by NMR. Proc Natl Acad Sci USA. 2007;104: 19773-19777.
33. Schroeder M, Cochlin L, Heather L, Clarke K, Radda G, Tyler D. In vivo assessment of pyruvate dehydrogenase flux in the heart using hyperpolarized carbon-13 magnetic resonance. Proc Natl Acad Sci USA. 2008;105:12051-12056.
34. Atherton HJ, Schroeder MA, Dodd MS, Heather L, Carter E, Cochlin LE, Nagel S, Sibson N, Radda GK, Clarke KC, Tyler DJ. Validation of the in vivo assessment of pyruvate dehydrogenase activity using hyperpolarised 13C-magnetic resonance spectroscopy. NMR Biomed. 2011;24: 201-208.
35. Schroeder MA, Atherton HJ, Ball D, Heather LC, Cole M, Griffin J, Clarke K, Radda GK, Tyler DJ. Real time assessment of Krebs cycle metabolism using hyperpolarized 13C magnetic resonance spectroscopy. FASEB J. 2009;23:2529-2538.
36. Schroeder MA, Dodd MS, Clarke K, Radda GK, Tyler DJ. Real time, in vivo observation of oxidative carbohydrate metabolism reveals the key regulatory role of acetyl-carnitine as a substrate buffer in the heart [abstract]. Circulation. 2009;120:S1099.
37. Shigenaga MK, Hagen TM, Ames BN. Oxidative damage and mitochondrial decay in aging. Proc Natl Acad Sci USA. 1994;91: 10771-10778. (Pubitemid 24349567)
38. Reibel DK, Uboh CE, Kent RL. Altered coenzyme A and carnitine metabolism in pressure-overload hypertrophied hearts. Am J Physiol. 1983;244:H839-H843. (Pubitemid 13066970)
39. Pierpont ME, Foker JE, Pierpont GL. Myocardial carnitine metabolism in congestive heart failure induced by incessant tachycardia. Basic Res Cardiol. 1993;88:362-370. (Pubitemid 23301329)
40. Paulson DJ. Carnitine deficiency-induced cardiomyopathy. Mol Cell Biochem. 1998;180:33-41. (Pubitemid 28118801)
41. Murray AJ, Anderson RE, Watson GC, Radda GK, Clarke K. Uncoupling proteins in human heart. Lancet. 2004;364:1786-1788. (Pubitemid 39488064)
42. Murray AJ, Panagia M, Hauton D, Gibbons GF, Clarke K. Plasma free fatty acids and peroxisome proliferator-activated receptor alpha in the control of myocardial uncoupling protein levels. Diabetes. 2005;54: 3496-3502. (Pubitemid 43334341)
43. Cross HR, Opie LH, Radda GK, Clarke K. Is a high glycogen content beneficial or detrimental to the ischemic rat heart? A controversy resolved. Circ Res. 1996;78:482-491.
44. Cross HR, Clarke K, Opie LH, Radda GK. Is lactate-induced myocardial ischaemic injury mediated by decreased pH or increased intracellular lactate? J Mol Cell Cardiol. 1995;27:1369-1381.
45. Taegtmeyer H. Metabolic responses to cardiac hypoxia: increased production of succinate by rabbit papillary muscles. Circ Res. 1978;43: 808-815. (Pubitemid 9054875)
46. Vaughan-Jones RD, Spitzer KW, Swietach P. Intracellular pH regulation in heart. J Mol Cell Cardiol. 2009;46:318-331.
47. Dennis SC, Gevers W, Opie LH. Protons in ischemia: where do they come from; where do they go to? J Mol Cell Cardiol. 1991;23: 1077-1086.
48. Camici P, Ferrannini E, Opie LH. Myocardial metabolism in ischemic heart disease: basic principles and application to imaging by positron emission tomography. Prog Cardiovasc Dis. 1989;32:217-238. (Pubitemid 19274897)
49. Merritt ME, Harrison C, Storey C, Sherry AD, Malloy CR. Inhibition of carbohydrate oxidation during the first minute of reperfusion after brief ischemia: NMR detection of hyperpolarized 13CO2 and H13CO3. Magn Reson Med. 2008;60:1029-1036.
50. Schroeder MA, Swietach P, Atherton HJ, Gallagher FA, Lee P, Radda GK, Clarke K, Tyler DJ. Measuring intracellular pH in the heart using hyperpolarized carbon dioxide and bicarbonate: a 13C and 31P magnetic resonance spectroscopy study. Cardiovasc Res. 2010;86:82-91.
51. Gallagher FA, Kettunen MI, Day SE, Hu DE, Ardenkjaer-Larsen JH, Zandt R, Jensen PR, Karlsson M, Golman K, Lerche MH, Brindle KM. Magnetic resonance imaging of pH in vivo using hyperpolarized 13Clabelled bicarbonate. Nature. 2008;453:940-943. (Pubitemid 351832568)
52. Swietach P, Vaughan-Jones RD, Harris AL. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev. 2007;26: 299-310. (Pubitemid 47101667)
53. Hoffman DW, Henkens RW. The rates of fast reactions of carbon dioxide and bicarbonate in human erythrocytes measured by carbon-13 NMR. Biochem Biophys Res Commun. 1987;143:67-73. (Pubitemid 17030465)
54. Brindle KM, Rajagopalan B, Williams DS, Detre JA, Simplaceanu E, Ho C, Radda GK. 31P NMR measurements of myocardial pH in vivo. Biochem Biophys Res Commun. 1988;151:70-77. (Pubitemid 18074146)
55. Zhou J, Payen JF, Wilson DA, Traystman RJ, van Zijl PC. Using the amide proton signals of intracellular proteins and peptides to detect pH effects in MRI. Nat Med. 2003;9:1085-1090. (Pubitemid 37021791)
56. Gertz EW, Wisneski JA, Neese R, Bristow JD, Searle GL, Hanlon JT. Myocardial lactate metabolism: evidence of lactate release during net chemical extraction in man. Circulation. 1981;63:1273-1279. (Pubitemid 11120662)
57. Khabbaz KR, Zankoul F, Warner KG. Intraoperative metabolic monitoring of the heart, II: online measurement of myocardial tissue pH. Ann Thorac Surg. 2001;72:S2227-2233. (Pubitemid 34001521)
58. Crittenden MD. Intraoperative metabolic monitoring of the heart, I: clinical assessment of coronary sinus metabolites. Ann Thorac Surg. 2001;72:S2220-S2226. (Pubitemid 34001519)
59. Panting JR, Gatehouse PD, Yang GZ, Grothues F, Firmin DN, Collins P, Pennell DJ. Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging. N Engl J Med. 2002;346:1948-1953. (Pubitemid 34651354)
60. Roberts WT, Bax JJ, Davies LC. Cardiac CT and CT coronary angiography: technology and application. Heart. 2008;94:781-792. (Pubitemid 351752298)
61. Kato S, Kitagawa K, Ishida N, Ishida M, Nagata M, Ichikawa Y, Katahira K, Matsumoto Y, Seo K, Ochiai R, Kobayashi Y, Sakuma H. Assessment of coronary artery disease using magnetic resonance coronary angiography: a national multicenter trial. J Am Coll Cardiol. 2010;56:983-991.
62. Golman K, Petersson JS. Metabolic imaging and other applications of hyperpolarized 13C1. Acad Radiol. 2006;13:932-942. (Pubitemid 44037467)
63. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503-1516. (Pubitemid 46588415)
64. Watkins S, McGeoch R, Lyne J, Steedman T, Good R, McLaughlin MJ, Cunningham T, Bezlyak V, Ford I, Dargie HJ, Oldroyd KG. Validation of magnetic resonance myocardial perfusion imaging with fractional flow reserve for the detection of significant coronary heart disease. Circulation. 2009;120:2207-2213.
65. Wolff SD, Schwitter J, Coulden R, Friedrich MG, Bluemke DA, Biederman RW, Martin ET, Lansky AJ, Kashanian F, Foo TK, Licato PE, Comeau CR. Myocardial first-pass perfusion magnetic resonance imaging: a multicenter dose-ranging study. Circulation. 2004;110:732-737. (Pubitemid 39056274)
66. Kety SS, Schmidt CF. The nitrous oxide method for the quantitative determination of cerebral blood flow in man: theory, procedure and normal values. J Clin Invest. 1948;27:476-483.
67. Gheorghiade M, Sopko G, De Luca L, Velazquez EJ, Parker JD, Binkley PF, Sadowski Z, Golba KS, Prior DL, Rouleau JL, Bonow RO. Navigating the crossroads of coronary artery disease and heart failure. Circulation. 2006;114:1202-1213. (Pubitemid 44386485)
68. Schinkel AF, Bax JJ, Poldermans D, Elhendy A, Ferrari R, Rahimtoola SH. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol. 2007;32:375-410. (Pubitemid 46881171)
69. Pagley PR, Beller GA, Watson DD, Gimple LW, Ragosta M. Improved outcome after coronary bypass surgery in patients with ischemic cardiomyopathy and residual myocardial viability. Circulation. 1997;96: 793-800. (Pubitemid 27329611)
70. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, Klocke FJ, Bonow RO, Judd RM. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343:1445-1453.
71. Rahimtoola SH. The hibernating myocardium. Am Heart J. 1989;117: 211-221.
72. Pegg TJ, Selvanayagam JB, Jennifer J, Francis JM, Karamitsos TD, Dall'Armellina E, Smith KL, Taggart DP, Neubauer S. Prediction of global left ventricular functional recovery in patients with heart failure undergoing surgical revascularisation, based on late gadolinium enhancement cardiovascular magnetic resonance. J Card Magn Reson. 2010;12:56.
73. Camici P. Heart failure: Advances in SPECT and PET for the management of heart failure. Heart. 2010;96:1932-1937.
74. Bengel FM, Higuchi T, Javadi MS, Lautamaki R. Cardiac positron emission tomography. J Am Coll Cardiol. 2009;54:1-15.
75. Selvanayagam JB, Kardos A, Francis JM, Wiesmann F, Petersen SE, Taggart DP, Neubauer S. Value of delayed-enhancement cardiovascular magnetic resonance imaging in predicting myocardial viability after surgical revascularization. Circulation. 2004;110:1535-1541. (Pubitemid 39297973)
76. Golman K, Petersson JS, Magnusson P, Johansson E, Akeson P, Chai CM, Hansson G, Mansson S. Cardiac metabolism measured noninvasively by hyperpolarized 13C MRI. Magn Reson Med. 2008;59: 1005-1013. (Pubitemid 351590513)
77. Klein C, Nekolla SG, Bengel FM, Momose M, Sammer A, Haas F, Schnackenburg B, Delius W, Mudra H, Wolfram D, Schwaiger M. Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging: comparison with positron emission tomography. Circulation. 2002;105:162-167. (Pubitemid 34084313)
78. Neubauer S, Krahe T, Schindler R, Horn M, Hillenbrand H, Entzeroth C, Mader H, Kromer EP, Riegger GA, Lackner K, Ertl G. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease: altered cardiac high-energy phosphate metabolism in heart failure. Circulation. 1992;86:1810-1818.
79. Lamb HJ, Beyerbacht HP, van der Laarse A, Stoel BC, Doornbos J, van der Wall EE, de Roos A. Diastolic dysfunction in hypertensive heart disease is associated with altered myocardial metabolism. Circulation. 1999;99:2261-2267. (Pubitemid 29201132)
80. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, Pabst T, Ertl G, Hahn D, Ingwall JS, Kochsiek K. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation. 1997;96:2190-2196. (Pubitemid 27425822)
81. Davila-Roman VG, Vedala G, Herrero P, de las Fuentes L, Rogers JG, Kelly DP, Gropler RJ. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2002;40:271-277. (Pubitemid 34756287)
82. Wallhaus TR, Taylor M, DeGrado TR, Russell DC, Stanko P, Nickles RJ, Stone CK. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation. 2001;103:2441-2446. (Pubitemid 32493369)
83. Taylor M, Wallhaus TR, Degrado TR, Russell DC, Stanko P, Nickles RJ, Stone CK. An evaluation of myocardial fatty acid and glucose uptake using PET with [18f]fluoro-6-thia-heptadecanoic acid and [18F]FDG in patients with congestive heart failure. J Nucl Med. 2001; 42:55-62. (Pubitemid 32104778)
84. Ukkonen H, Beanlands RS, Burwash IG, de Kemp RA, Nahmias C, Fallen E, Hill MR, Tang AS. Effect of cardiac resynchronization on myocardial efficiency and regional oxidative metabolism. Circulation. 2003;107:28-31. (Pubitemid 36070928)
85. Beanlands RS, Nahmias C, Gordon E, Coates G, deKemp R, Firnau G, Fallen E. The effects of beta(1)-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction: a double-blind, placebo-controlled, positron-emission tomography study. Circulation. 2000;102:2070-2075.
86. Ingwall JS, Weiss RG. Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ Res. 2004;95: 135-145. (Pubitemid 38988679)
87. Horowitz JD, Kennedy JA. Time to address the cardiac metabolic "triple whammy" ischemic heart failure in diabetic patients. J Am Coll Cardiol. 2006;48:2232-2234.
88. Atherton HJ, Dodd MS, Carr CA, Stuckey DJ, Schroeder MA, Clarke K, Radda GK, Tyler DJ. Investigating the metabolic effects of heart failure progression using hyperpolarized magnetic resonance. Int Soc Magn Reson Med. 2010.
89. Schroeder MA, Lau A, Barry J, Clarke K, Connelly K, Wright G, Cunningham C. Assessment of in vivo metabolism in failing hearts using hyperpolarized 13C magnetic resonance. J Cardio Magn Reson. 2011;13(Suppl 1):O79.
90. Ingwall JS. Energy metabolism in heart failure and remodelling. Cardiovasc Res. 2009;81:412-419.
91. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme a thiolase. Circ Res. 2000;86:580-588. (Pubitemid 30165050)
92. Tuunanen H, Engblom E, Naum A, Nagren K, Scheinin M, Hesse B, Juhani Airaksinen KE, Nuutila P, Iozzo P, Ukkonen H, Opie LH, Knuuti J. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation. 2008;118: 1250-1258.
93. Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Williams L, Ashrafian H, Horowitz J, Fraser AG, Clarke K, Frenneaux M. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation. 2005;112:3280-3288. (Pubitemid 43739373)
94. Lionetti V, Linke A, Chandler MP, Young ME, Penn MS, Gupte S, d'Agostino C, Hintze TH, Stanley WC, Recchia FA. Carnitine palmitoyl transferase-I inhibition prevents ventricular remodeling and delays decompensation in pacing-induced heart failure. Cardiovasc Res. 2005; 66:454-461. (Pubitemid 40725757)
95. Maya L, Villarreal FJ. Diagnostic approaches for diabetic cardiomyopathy and myocardial fibrosis. J Mol Cell Cardiol. 2010;48:524-529.
96. Aneja A, Tang WH, Bansilal S, Garcia MJ, Farkouh ME. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med. 2008;121:748-757.
97. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation. 2007;115:3213-3223. (Pubitemid 47012236)
98. Scheuermann-Freestone M, Madsen PL, Manners D, Blamire AM, Buckingham RE, Styles P, Radda GK, Neubauer S, Clarke K. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation. 2003;107:3040-3046. (Pubitemid 36758977)
99. Taegtmeyer H, McNulty P, Young ME. Adaptation and maladaptation of the heart in diabetes, part I: general concepts. Circulation. 2002;105: 1727-1733. (Pubitemid 34298619)
100. Lopaschuk GD. Metabolic abnormalities in the diabetic heart. Heart Fail Rev. 2002;7:149-159. (Pubitemid 34624803)
101. Wu P, Sato J, Zhao Y, Jaskiewicz J, Popov KM, Harris RA. Starvation and diabetes increase the amount of pyruvate dehydrogenase kinase isoenzyme 4 in rat heart. Biochem J. 1998;329(pt 1):197-201. (Pubitemid 28022309)
102. Kerbey AL, Randle PJ, Cooper RH, Whitehouse S, Pask HT, Denton RM. Regulation of pyruvate dehydrogenase in rat heart: mechanism of regulation of proportions of dephosphorylated and phosphorylated enzyme by oxidation of fatty acids and ketone bodies and of effects of diabetes: role of coenzyme a, acetyl-coenzyme a and reduced and oxidized nicotinamide-adenine dinucleotide. Biochem J. 1976;154: 327-348.
103. Wieland O, Siess E, Schulze-Wethmar FH, von Funcke HG, Winton B. Active and inactive forms of pyruvate dehydrogenase in rat heart and kidney: effect of diabetes, fasting, and refeeding on pyruvate dehydrogenase interconversion. Arch Biochem Biophys. 1971;143:593-601.
104. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care. 2004;27:1335-1342. (Pubitemid 38679980)
105. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, Stolarski C, Shen YT, Shannon RP. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation. 2004;110:955-961. (Pubitemid 39128621)
106. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-1705. (Pubitemid 46048557)
107. Bergmann SR, Herrero P, Sciacca R, Hartman JJ, Rubin PJ, Hickey KT, Epstein S, Kelly DP. Characterization of altered myocardial fatty acid metabolism in patients with inherited cardiomyopathy. J Inherit Metab Dis. 2001;24:657-674. (Pubitemid 33130087)
108. Arad M, Maron BJ, Gorham JM, Johnson WH Jr, Saul JP, Perez-Atayde AR, Spirito P, Wright GB, Kanter RJ, Seidman CE, Seidman JG. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med. 2005;352:362-372.
109. Waber LJ, Valle D, Neill C, DiMauro S, Shug A. Carnitine deficiency presenting as familial cardiomyopathy: a treatable defect in carnitine transport. J Pediatr. 1982;101:700-705.
110. Atherton HJ, Dodd MS, Heather LC, Schroeder MA, Griffin JL, Radda GK, Clarke K, Tyler DJ. Role of pyruvate dehydrogenase inhibition in the development of hypertrophy in the hyperthyroid rat heart: a combined magnetic resonance imaging and hyperpolarized magnetic resonance spectroscopy study. Circulation. 2011;123:2552-2561.
111. Buccino RA, Spann JF Jr, Pool PE, Sonnenblick EH, Braunwald E. Influence of the thyroid state on the intrinsic contractile properties and energy stores of the myocardium. J Clin Invest. 1967;46:1669-1682.
112. Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, McKenna WJ, Elliott PM. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation. 2002;105: 1407-1411. (Pubitemid 34263268)
113. Frustaci A, Chimenti C, Ricci R, Natale L, Russo MA, Pieroni M, Eng CM, Desnick RJ. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl J Med. 2001;345:25-32. (Pubitemid 32634268)
114. Lau AZ, Chen AP, Ghugre NR, Ramanan V, Lam WW, Connelly KA, Wright GA, Cunningham CH. Rapid multislice imaging of hyperpolarized (13)C pyruvate and bicarbonate in the heart. Magn Reson Med. 2010;64:1323-1331.
115. Larson PE, Bok R, Kerr AB, Lustig M, Hu S, Chen AP, Nelson SJ, Pauly JM, Kurhanewicz J, Vigneron DB. Investigation of tumor hyperpolarized [1-13C]-pyruvate dynamics using time-resolved multiband RF excitation echo-planar MRSI. Magn Reson Med. 2010;63:582-591.
116. Chen AP, Leung K, Lam W, Hurd RE, Vigneron DB, Cunningham CH. Design of spectral-spatial outer volume suppression RF pulses for tissue specific metabolic characterization with hyperpolarized 13C pyruvate. J Magn Reson. 2009;200:344-348.
117. Gallagher FA, Kettunen MI, Hu DE, Jensen PR, Zandt RI, Karlsson M, Gisselsson A, Nelson SK, Witney TH, Bohndiek SE, Hansson G, Peitersen T, Lerche MH, Brindle KM. Production of hyperpolarized [1,4-13C2]malate from [1,4-13C2]fumarate is a marker of cell necrosis and treatment response in tumors. Proc Natl Acad Sci USA. 2009;106: 19801-19806.
118. Jensen PR, Peitersen T, Karlsson M, Zandt R, Gisselsson A, Hansson G, Meier S, Lerche MH. Tissue-specific short chain fatty acid metabolism and slow metabolic recovery after ischemia from hyperpolarized NMR in vivo. J Biol Chem. 2009;284:36077-36082.
119. Wilson DM, Hurd RE, Keshari K, Van Criekinge M, Chen AP, Nelson SJ, Vigneron DB, Kurhanewicz J. Generation of hyperpolarized substrates by secondary labeling with [1,1-13C] acetic anhydride. Proc Natl Acad Sci USA. 2009;106:5503-5507.
120. Warren WS, Jenista E, Branca RT, Chen X. Increasing hyperpolarized spin lifetimes through true singlet eigenstates. Science. 2009;323: 1711-1714.
121. Johannesson H, Macholl S, Ardenkjaer-Larsen JH. Dynamic nuclear polarization of [1-13C]pyruvic acid at 4.6 Tesla. J Magn Reson. 2009; 197:167-175.
122. Lau AZ, Chen AP, Schroeder MA, Lam WW, Gu Y, Barry J, Cunningham CH. Free-breathing cardiac and respiratory-gated imaging of hyperpolarized pyruvate and bicarbonate in the heart. Proc Intl Soc Mag Reson Med. 2011;19:3532.
123. Keshari KR, Wilson DM, Chen AP, Bok R, Larson PE, Hu S, Van Criekinge M, Macdonald JM, Vigneron DB, Kurhanewicz J. Hyperpolarized [2-13C]-fructose: a hemiketal DNP substrate for in vivo metabolic imaging. J Am Chem Soc. 2009;131:17591-17596.
124. Wilson DM, Keshari KR, Larson PE, Chen AP, Hu S, Van Criekinge M, Bok R, Nelson SJ, Macdonald JM, Vigneron DB, Kurhanewicz J. Multi-compound polarization by DNP allows simultaneous assessment of multiple enzymatic activities in vivo. J Magn Reson. 2010;205:141-147.